Current therapies for pulmonary arterial hypertension (PAH, group 1) work through four major pathways: endothelin-1, nitric oxide, prostacyclin and bone morphogenetic protein/activin signaling. The gene discussed is INHBE; the disease is pulmonary arterial hypertension.